您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Trilaciclib hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Trilaciclib hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Trilaciclib hydrochloride图片
CAS NO:1977495-97-8
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品名称
G1T28 hydrochloride
产品介绍
Trilaciclib hydrochloride (G1T28 hydrochloride) 是CDK4/6的抑制剂,对 CDK4 和 CDK6 的IC50值分别为 1 nM 和 4 nM。
生物活性

Trilaciclib hydrochloride (G1T28 hydrochloride) is aCDK4/6inhibitor withIC50s of 1 nM and 4 nM forCDK4andCDK6, respectively[1].

IC50& Target

Cdk4/cyclin D1

1 nM (IC50)

cdk6/cyclin D3

4 nM (IC50)

体外研究
(In Vitro)

Incubation with Trilaciclib hydrochloride (G1T28) for 24 hours induces a robust G1cell-cycle arrest (time=0). By 16 hours after Trilaciclib hydrochloride washout, cells have reentered the cell cycle and demonstrate cell-cycle kinetics similar to untreated control cells. These results demonstrate that Trilaciclib hydrochloride causes a transient, and reversible G1arrest. A transient Trilaciclib hydrochloride-mediated G1cell-cycle arrest in CDK4/6-sensitive cells decreases thein vitrotoxicity of a variety of commonly used cytotoxic chemotherapy agents associated with myelosuppression[1].

体内研究
(In Vivo)

Trilaciclib hydrochloride (G1T28) treatment results in a robust and dose-dependent suppression of proliferation in HSPCs at 12 hours, with 5-ethynyl-2′-deoxyuridine (EdU) incorporation returning near baseline levels in a dose-dependent manner by 24 hours after administration. These data demonstrate that a single oral dose of Trilaciclib hydrochloride can produce reversible cell-cycle arrest in HSPCs in a dose-dependent mannerin vivo. Mice given 100 mg/kg Trilaciclib hydrochloride 30 minutes prior to etoposide treatment, exhibits only background levels of caspase-3/7 activity. These data demonstrate that Trilaciclib hydrochloride can protect the bone marrow from chemotherapy-induced apoptosisin vivo. The data demonstrate that treatment with Trilaciclib hydrochloride prior to 5-fluorouracil (5-FU) likely decreases 5-FU-induced damage by chemotherapy in HSPCs, thus accelerating blood count recovery after chemotherapy[1].

Clinical Trial
分子量

519.47

性状

Solid

Formula

C24H32Cl2N8O

CAS 号

1977495-97-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 25.64 mg/mL(49.36 mM;ultrasonic and adjust pH to 2 with HCl)

DMSO : 1.1 mg/mL(2.12 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.9250 mL9.6252 mL19.2504 mL
5 mM0.3850 mL1.9250 mL3.8501 mL
10 mM0.1925 mL0.9625 mL1.9250 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。